E
Emon Elboudwarej
Researcher at Cedars-Sinai Medical Center
Publications - 5
Citations - 2315
Emon Elboudwarej is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications receiving 1879 citations.
Papers
More filters
Journal ArticleDOI
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Jonathan Grein,Norio Ohmagari,Daniel Shin,George Diaz,Erika Asperges,Antonella Castagna,Torsten Feldt,Gary M. Green,Margaret L. Green,François-Xavier Lescure,Emanuele Nicastri,Rentaro Oda,Kikuo Yo,Eugenia Quiros-Roldan,Alex Studemeister,John Redinski,Seema Ahmed,Jorge Bernett,Daniel Chelliah,Danny Chen,Shingo Chihara,Stuart H. Cohen,Jennifer Cunningham,Antonella D’Arminio Monforte,Saad Ismail,Hideaki Kato,Giuseppe Lapadula,Erwan L’Her,Toshitaka Maeno,Sumit Majumder,Marco Massari,Marta Mora-Rillo,Yoshikazu Mutoh,Duc Nguyen,Ewa Verweij,Alexander Zoufaly,Anu Osinusi,Adam DeZure,Yang Zhao,Lijie Zhong,Anand Chokkalingam,Emon Elboudwarej,Laura Telep,Leighann Timbs,Ilana Henne,Scott Sellers,Huyen Cao,Susanna K. Tan,Lucinda Winterbourne,Polly Desai,Robertino Mera,Anuj Gaggar,Robert P. Myers,Diana M. Brainard,Richard Childs,Timothy Flanigan +55 more
TL;DR: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients, and Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesavir therapy.
Journal ArticleDOI
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
Sam Brown,Morgan J. Katz,Adit A. Ginde,Kavita Juneja,M. Ramchandani,Joshua T. Schiffer,Carlos Silva Vaca,Robert L. Gottlieb,Yupeng Tian,Emon Elboudwarej,Joshua A. Hill,Richard Gilson,Lauren Rodriguez,Charlotte Hedskog,Shuguang Chen,Jairo M. Montezuma-Rusca,Anu Osinusi,Roger Paredes +17 more
TL;DR: In this paper , the authors reported results of assessment of heterogeneity of treatment effect of early outpatient remdesivir, focusing on time from symptom onset and number of baseline risk factors (RFs).
Journal ArticleDOI
Abstract 4396: TROP2 expression in non-small cell lung cancer
TL;DR: In this article , the authors characterized TROP2 expression across three independent datasets to explore the trphoblast cell-surface antigen 2 (TROP2) relationship to baseline characteristics, molecular features of interest, and its prognostic value in NSCLC.
Journal ArticleDOI
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.
Yohann Loriot,Arjun Vasant Balar,Daniel P. Petrylak,Arash Rezazadeh,Petros Grivas,Aude Flechon,Rohit Jain,Neeraj Agarwal,Manoj Bupathi,P. Barthelemy,Philippe Beuzeboc,Phillip L. Palmbos,Christos Kyriakopoulos,Damien Pouessel,Cora N. Sternberg,Julia Tonelli,Emon Elboudwarej,Lauri Diehl,Juliane M. Jürgensmeier,Scott T. Tagawa +19 more
TL;DR: In this article , Trop-2-directed antibody-drug conjugate with accelerated FDA approval for pts with LA unresectable or mUC who previously received platinum (PT) and a checkpoint inhibitor (CPI).
Journal ArticleDOI
Abstract 4392: Expression landscape of trophoblast cell surface antigen 2 (Trop-2) in breast cancer
Kaiwei Song,O.K. Yoon,Luting Zhuo,Emon Elboudwarej,Biao Li,Jillian Boice,Yang Pan,S Phan,Monica Motwani +8 more
TL;DR: Song et al. as discussed by the authors evaluated RNA expression data in breast cancer from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).